148 related articles for article (PubMed ID: 38619177)
21. Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors.
Zeng Y; Ling Y; Chen X; Ding C; Jin Y; Feng S; Chen Z; Guo J; Qiu H
Oncol Lett; 2024 Mar; 27(3):133. PubMed ID: 38362234
[TBL] [Abstract][Full Text] [Related]
22. Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10 cm: A Single-Institution Experience in China.
Shen C; Chen H; Yin Y; Chen J; Tang S; Zhang B; Han L; Chen Z; Chen J
Medicine (Baltimore); 2015 Jul; 94(28):e1117. PubMed ID: 26181546
[TBL] [Abstract][Full Text] [Related]
23. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
24. Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry.
Lee SH; Jin YJ; Lee JW
Medicine (Baltimore); 2017 Nov; 96(44):e8486. PubMed ID: 29095307
[TBL] [Abstract][Full Text] [Related]
25. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
[TBL] [Abstract][Full Text] [Related]
26. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
28. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
[TBL] [Abstract][Full Text] [Related]
30. Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.
Xu J; Ling TL; Wang M; Zhao WY; Cao H
Int Surg; 2015 May; 100(5):860-9. PubMed ID: 26011207
[TBL] [Abstract][Full Text] [Related]
31. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
Blesius A; Cassier PA; Bertucci F; Fayette J; Ray-Coquard I; Bui B; Adenis A; Rios M; Cupissol D; Pérol D; Blay JY; Le Cesne A
BMC Cancer; 2011 Feb; 11():72. PubMed ID: 21324142
[TBL] [Abstract][Full Text] [Related]
33. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
34. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
35. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
[TBL] [Abstract][Full Text] [Related]
36. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Yeh CN; Wang SY; Tsai CY; Chen YY; Liu CT; Chiang KC; Chen TW; Liu YY; Yeh TS
Int J Surg; 2017 Mar; 39():30-36. PubMed ID: 28110026
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
[TBL] [Abstract][Full Text] [Related]
38. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
39. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy.
Sakakura C; Hagiwara A; Soga K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yamaoka N; Sagara Y; Yamagishi H
World J Gastroenterol; 2006 May; 12(17):2793-7. PubMed ID: 16718773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
